Late-Onset Neutropenia After Rituximab in Multiple Sclerosis: Incidence, Predictors, and Outcomes in a Retrospective Multicenter Cohort. (PubMed, Neurol Neuroimmunol Neuroinflamm) - Sep 16, 2026 - "In this large real-world cohort, high-grade LON (grades 3-4) events were rare and frequently complicated by infections. Mild (grade 2) LON events were often fluctuating and generally clinically uneventful. Rechallenge with rituximab was rarely complicated by serious adverse events. Prediction of LON remains challenging, highlighting the relevance of infection vigilance during anti-CD20 therapy."
Journal • Retrospective data • CNS Disorders • Hematological Disorders • Infectious Disease • Multiple Sclerosis • Neutropenia
|
|
Anders Svenningsson; Björn Evertsson; Jan Lycke; Jonatan Salzer; Katharina Fink; Malin Boremalm; Pierre de Flon; Sandra Kallin; Susanna Hallberg
|